New Hampshire to offer Gardasil vaccinations free to all girls

Share this article:
New Hampshire health officials plan to offer Merck’s Gardasil human papillomavirus (HPV) vaccine free to all girls to help protect them against cervical cancer. “New Hampshire will be the first state in the country to offer the vaccine in its universal children’s (vaccine) program,” New Hampshire Health and Human Services Commissioner John Stephen told the Associated Press. The New Hampshire Vaccines for Children program is funded by the federal government and private insurers and offers “no-cost” immunizations to children through age 18. The program also pays to vaccinate children against other diseases, such as hepatits A and B, polio and measles. A total of $4.8 million has been budgeted for the vaccine next year, reports said. New Hampshire officials gave doctors the OK to begin ordering the vaccine last Friday, for shipment in January. State officials hope 17,000 young women—25% of those eligible—will come forward for the vaccinations during 2007. Gardasil was approved by the FDA in June for females nine to 26 years old. The vaccine helps protect against four types of HPV responsible for most strains of the disease. A Centers for Disease Control and Prevention panel recommended Gardasil for use in girls 11 and 12, and down to nine per a physician’s discretion, and for all those not vaccinated from 13 to 26.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.